NASDAQ:BCTX Briacell Therap Q3 2026 Earnings Results & Report $3.77 +0.08 (+2.17%) Closing price 10/15/2026 03:51 PM EasternExtended Trading$3.72 -0.04 (-1.19%) As of 06:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Briacell Therap reported Q3 2026 earnings on June 9, 2026. The company reported EPS of -$0.99. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateJune 9, 2026TimeAfter Market ClosesConference Call7:00 AM ET Briacell Therap EPS ResultsActual EPS-$0.99Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersBriacell Therap Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Briacell Therap Q3 2026 Earnings FAQ Did Briacell Therap beat earnings estimates for Q3 2026? Briacell Therap (NASDAQ:BCTX) reported earnings of -$0.99 per share for Q3 2026. The report was announced on Tuesday, June 9, 2026. Briacell Therap Earnings HeadlinesBriacell Therap (NASDAQ:BCTX) Shares Down 0.5% - Here's What HappenedOctober 8, 2026 | americanbankingnews.comBriaCell and BriaPro to Present Four Posters at SITC 2026 Annual MeetingOctober 6, 2026 | globenewswire.comElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men described the same moment in strikingly similar terms: a technological tipping point they call the Singularity. James Altucher says the idea once belonged to science fiction. Now he connects it to a move Musk could make as soon as October 21, and lays out what both men see coming in a short presentation.October 16 at 1:00 AM | Paradigm Press (Ad)Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer StudySeptember 14, 2026 | markets.businessinsider.comData Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer StudySeptember 14, 2026 | globenewswire.comBriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer CenterSeptember 8, 2026 | globenewswire.comSee More Briacell Therap Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Briacell Therap? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Briacell Therap and other key companies, straight to your email. Email Address About Briacell TherapBriacell Therap (NASDAQ:BCTX)eutics Corp. (NASDAQ: BCTX) is a clinical-stage biotechnology company developing targeted immunotherapies for cancer. The company focuses primarily on treatments for advanced breast cancer, with an emphasis on stimulating a patient’s immune system to recognize and attack tumor cells. BriaCell’s lead product candidate is Bria-IMT, an immunotherapy derived from a breast cancer cell line and designed to activate cancer-fighting immune responses. The company has evaluated Bria-IMT in clinical studies for metastatic breast cancer, including in combination with immune checkpoint inhibitors. BriaCell is also developing Bria-OTS, an off-the-shelf immunotherapy platform intended to provide broader patient compatibility while supporting personalized cancer treatment approaches. BriaCell Therapeutics is headquartered in Vancouver, British Columbia, and conducts its research and clinical development activities in North America. The company’s programs remain investigational and are subject to clinical and regulatory review. William Williams has served as the company’s president and chief executive officer.View Briacell Therap ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026)GE Aerospace (10/20/2026)3M (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
